PMCID: PMC8949037
3.1.1 3D organoid cultures 3D organoids are derived from organs, tumours, or stem cells that recapitulate native tissue structure and function for studying disease development and personalized medicine (Figure 2
Disclosures: Eunho Choi: Nothing to Disclose, Young-Sun Lee: Nothing to Disclose, Jeong-An Gim: Nothing to Disclose, Wonhyo Seo: Nothing to Disclose, Ha Seok Lee: Nothing to Disclose, Youngwoo Lee: Nothing to Disclose, Yang Jae Yoo: Nothing to Disclose, Seong Hee Kang: Nothing to Disclose, Sun Young Yim: Nothing to Disclose, Young Kul Jung: Nothing to Disclose, Ji Hoon Kim: Nothing to Disclose, Yeon Seok Seo: Nothing to Disclose, Hyung Joon Yim: Nothing to Disclose, Jong Eun Yeon: Nothing to Disclose, Kwan Soo Byun: Nothing to Disclose 1915 THE COMPOSITION OF CIRCULATING IMMUNE CELLS FOLLOWING TREATMENT WITH ATEZOLIZUMAB AND BEVACIZUMAB IN ADVANCED HEPATOCELLULAR CARCINOMA Eunho Choi 1 Ha Seok Lee 1 Young-Sun Lee 1 Youngwoo Lee 1 Yang Jae Yoo 1 Seong Hee Kang 1 Sun Young Yim 1 Young Kul Jung 1 Ji Hoon Kim 1 Yeon Seok Seo 1 Hyung Joon Yim 1 Jong Eun Yeon 1 Kwan Soo Byun 1 , 1 Korea University College of Medicine Background: Currently, combination therapy of atezolizumab and bevacizumab is used as a first-line therapy for advanced hepatocellular carcinoma
These comprise the low density basement membrane in the space of Disse
